HTG EdgeSeq analysis of parental and CDK4/6i-resistant (Ribociclib or Palbociclib) T47D breast cancer cell clones
Do illuminate the vulnerabilities of CDK4/6i-resistant T47D breast cancer cells, we created CDK4/6i-resistant T47D cell clones through a gradual dose escalation protocol using the selective CDK4/6 inhibitors Ribociclib and Palbociclib. We then performed gene expression analysis targeting 2549 genes using the HTG Oncology Biomarker Panel (OBP) via HTG EdgeSeq.
Do illuminate the vulnerabilities of CDK4/6i-resistant T47D breast cancer cells, we created CDK4/6i-resistant T47D cell clones through a gradual dose escalation protocol using the selective CDK4/6 inhibitors Ribociclib and Palbociclib. We then performed gene expression analysis targeting 2549 genes using the HTG Oncology Biomarker Panel (OBP) via HTG EdgeSeq.
European Bioinformatics Institute